2.12
0.03 (1.44%)
| Penutupan Terdahulu | 2.09 |
| Jumlah Dagangan | 345,143 |
| Harga / Jualan (P/S) | 3.54 |
| Harga / Buku (P/B) | 1.85 |
| Julat 52 Minggu |
| Margin Operasi (TTM) | -41,252.01% |
| EPS Cair (TTM) | -0.870 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 103.60% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 1.00% |
| Nisbah Semasa (MRQ) | 5.28 |
| Aliran Tunai Operasi (OCF TTM) | -47.70 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 34.37 M |
| Pulangan Atas Aset (ROA TTM) | -34.47% |
| Pulangan Atas Ekuiti (ROE TTM) | -54.13% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | InflaRx N.V. | Bercampur | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -3.5 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -0.5 |
| Purata | -0.50 |
|
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 6.44% |
| % Dimiliki oleh Institusi | 26.24% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |